

RECEIVED
CENTRAL FAX CENTER

JAN 18 2006

SCHERING-PLOUGH CORPORATION
LAW DEPARTMENT
2000 GALLOPING HILL ROAD
K-6-1, MAIL STOP 1990
KENILWORTH, NEW JERSEY 07033
(908) 298-4000

FACSIMILE TRANSMITTAL SHEET

TO:	Examiner: P. Ward USPTO	FAX NUMBER:	(571) 273-8300
FROM:	Palaiyur S. Kalyanaraman	PHONE NUMBER:	(908) 298-5068
TOTAL NO. OF PAGES INCLUDING COVER	6	DATE:	January 18, 2006

CONFIDENTIALITY NOTE: This sheet and/or the document(s) accompanying it contain information belonging to Schering-Plough Corporation and/or its affiliates which is confidential and/or legally privileged. The information is intended only for the use of the individual or entity named above. If you have received this fax in error, please immediately notify us by telephone. If there is a problem with this transmission please call Ashly Armstrong at (908) 298-4025.

NOTES/COMMENTS:

PLEASE HAND DELIVER

In re Application of: M. Dwyer *et al.*
For Patent entitled: "Novel Pyrazolopyridines as Cyclin Dependent Kinase Inhibitors"
Group Art Unit: 1623
Filed: 09/17/2003
Attorney Docket No.: OC01629K
Serial No.: 10/664,337

Dear Examiner Ward,

Transmitted herewith are:

- Fax Cover Sheet – 1pg.
- Cert. of Transmission – 1pg.
- Response Transmittal – 1pg.
- Response to Restriction Req. and Election of Species – 3pgs.



Palaiyur S. Kalyanaraman
Registered Representative
Registration No. 34,634

PHONE: (908) 298-5068

FAX: (908) 298-5388

Docket Number: OC01629K
Application No: 10/664,337
Filing Date: 09/17/2003
First Inventor: DWYER, Michael P.

PTO/SB/97 (09-04)
Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office at (571) 273-8300

on 01/18/2006
Date


Signature

PALAIYUR S. KALYANARAMAN

Typed or printed name of person signing Certificate

34,634

Registration Number, if applicable

908-298-5068

Telephone Number

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Fax Cover Sheet - 1pg.

Cert. of Transmission - 1pg.

Response Transmittal - 1pg.

Response to Restriction Req. and Election of Species - 3pgs.

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED
CENTRAL FAX CENTER

JAN 18 2006

Express Mail Label:

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031


U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/664,337	
	Filing Date	09/17/2003	
	First Named Inventor	DWYER, Michael P.	
	Art Unit	1623	
	Examiner Name	P. Ward	
Total Number of Pages in This Submission	6	Attorney Docket Number	OC01629K

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): <div style="text-align: center;">Fax Cover Sheet - 1pg. ; Cert. of Transmission - 1pg.</div>
<div style="border: 1px solid black; height: 40px; width: 100%;"></div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Customer No: 24265		
Signature			
Printed name	PALAIYUR S. KALYANARAMAN		
Date	01/18/2006	Reg. No.	34,634

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:			
Signature			
Typed or printed name		Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED
CENTRAL FAX CENTER

JAN 18 2006

PATENT: OC01629K

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

-----X	
In re Application of:	:
	:
M. Dwyer et al.	:
	:
Serial No.: 10/664,337	:
	:
Filed: September 17, 2003	:
	:
For: "Novel Pyrazolopyridines as Cyclin	:
Dependent Kinase Inhibitors"	:
-----X	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT AND ELECTION OF
SPECIES

Sir:

This communication is in response to the Official Action dated December 27, 2005, on the subject patent application. This communication is being faxed to the Examiner's attention at 571-273-8300.

Claims 1-28 are pending in the case. The Examiner restricted the invention into four groups:

Group I: The compounds and compositions according to claim 1, Formula III, wherein R³ contains a heteroaryl/heterocyclyl moiety;

Group II: The compounds and compositions according to claim 1, Formula III, wherein R³ contains a non-heteroaryl/non-heterocyclyl moiety;

Group III: The method of treating according to claims 17-25, wherein R³ contains a heteroaryl/heterocyclyl moiety; and

Group IV: The method of treating according to claims 17-25, wherein R³ contains a non-heteroaryl/non-heterocyclyl moiety

If electing from among Groups I-IV, the Examiner additionally required the election of a single disclosed species for prosecution on the merits.

Applicants believe that all claims 1-28 form part of one and the same invention. Applicants further believe that when there is a linking claim (claim 1

- 2 -


here) encompassing the scope of all the processes, uses, composition and compounds, it is inappropriate to restrict the invention into these various inventions. Applicants also believe that due to such commonality, a complete examination of claims 1-27 as filed would not cause undue burden. Applicants further believe that the same art search will most probably apply to the alleged separate inventions, and respectfully submit that the restriction is improper.

Under the statute "two or more independent and distinct inventions.... in one application may.... be restricted to one of the inventions." Inventions are "independent" if "there is no disclosed relationship between two or more subjects disclosed" (MPEP 802.01). The term "distinct" means that "two or more subjects as disclosed are related.... but are capable of separate manufacture, use or sale as claimed, and are patentable over each other" (MPEP 802.01). However, even when patentably distinct inventions, restriction is not required unless one of the following reasons appear (MPEP 808.02):

1. Separate classification
2. Separate status in the art; or
3. Different field of search.

In the present application, Applicant believes that the Examiner has not established a clear reason to establish the existence of any of the above 3 groups. Reconsideration and withdrawal of the restriction requirement are, therefore, respectfully requested.

However, in the interest of advancing the prosecution, Applicants elect, with traverse, the invention cited as Group II for prosecution on the merits, and elect the following species:



again with traverse. This compound is shown as Compound No. 32 on page 31 of the specification, as well as in Claim 15.

- 3 -

If the Examiner has any questions, the Examiner is invited to contact the undersigned.

January 18, 2006
Schering-Plough Corporation
2000 Galloping Hill Road
Patent Department, K-6-1, 1990
Kenilworth, NJ 07033
Tel: (908) 298-5068
Fax: (908) 298-5388

Respectfully submitted,



Dr. Palaiyur S. Kalyanaraman
Attorney for Applicants
Reg. No. 34,634